tenofovir has been researched along with Sexually Transmitted Disease, Viral in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PL; De Boni, RB; Freitas, L; Goulart, S; Grinsztejn, B; Hoagland, B; Kallas, EG; Leite, IC; Liu, A; Luz, PM; Madruga, JV; Martins, LMS; Moreira, RI; Torres, TS; Vasconcelos, R; Veloso, VG | 1 |
| Bradshaw, CS; Chen, MY; Chow, EPF; Cornelisse, VJ; Fairley, CK; Fortune, R; Needleman, R; Towns, JM; Yang, TZT | 1 |
| Eichner, A; Shalit, P; Thomas, A; Tung, EL | 1 |
| Baum, MM; Kennedy, S; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
| Hedrick, JL; Ke, X; Lee, AL; Ng, VW; Poon, GL; Yang, YY | 1 |
| Ariën, KK; Vanham, G | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
1 trial(s) available for tenofovir and Sexually Transmitted Disease, Viral
| Article | Year |
|---|---|
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Topics: Administration, Oral; Adult; Brazil; Emtricitabine; Feasibility Studies; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexually Transmitted Diseases, Viral; Tenofovir; Transgender Persons; Young Adult | 2018 |
6 other study(ies) available for tenofovir and Sexually Transmitted Disease, Viral
| Article | Year |
|---|---|
Access to sexual health services after the rapid roll out of the launch of pre-exposure prophylaxis for HIV in Melbourne, Australia: a retrospective cross-sectional analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Therapy, Combination; Emtricitabine; Female; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Retrospective Studies; Sexually Transmitted Diseases, Viral; Tenofovir; Victoria | 2018 |
Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Community Pharmacy Services; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Sexually Transmitted Diseases, Viral; Tenofovir; Washington | 2018 |
Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Retroviral Agents; Biopsy; Contraceptive Agents; Desogestrel; Drug Evaluation, Preclinical; Estradiol; Female; Intrauterine Devices, Medicated; Models, Animal; Nevirapine; Organophosphonates; Saquinavir; Sexually Transmitted Diseases, Viral; Sheep; Tenofovir; Time Factors | 2013 |
Co-delivery of antiviral and antifungal therapeutics for the treatment of sexually transmitted infections using a moldable, supramolecular hydrogel.
Topics: Animals; Antifungal Agents; Antiviral Agents; Biofilms; Candida albicans; Cells, Cultured; Drug Delivery Systems; Drug Evaluation, Preclinical; Fibroblasts; Humans; Hydrogels; Mice; Microbial Sensitivity Tests; Polycarboxylate Cement; Polyethylene Glycols; Sexually Transmitted Diseases; Sexually Transmitted Diseases, Viral; Tenofovir; Vitamin D | 2015 |
First real success for anti-HIV gel: a new start for HIV microbicides?
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Controlled Clinical Trials as Topic; Disease Transmission, Infectious; Female; HIV Infections; Humans; Organophosphonates; Sexually Transmitted Diseases, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Equipment Design; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Rabbits; Sexually Transmitted Diseases, Viral; Tenofovir; Treatment Outcome | 2012 |